Buchumschlag

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

The Associazione Italiana di Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Acute Lymphoblastic Leukemia (AIEOP-BFM ALL 2000) study has for the first time introduced standardized quantitative assessment of minimal residual disease (MRD) based on immunoglobulin and T-cell receptor...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Conter, Valentino (VerfasserIn) , Bartram, Claus R. (VerfasserIn) , Valsecchi, Maria Grazia (VerfasserIn) , Schrauder, André (VerfasserIn) , Panzer-Grümayer, Renate (VerfasserIn) , Möricke, Anja (VerfasserIn) , Aricò, Maurizio (VerfasserIn) , Zimmermann, Martin (VerfasserIn) , Mann, Georg (VerfasserIn) , De Rossi, Giulio (VerfasserIn) , Stanulla, Martin (VerfasserIn) , Locatelli, Franco (VerfasserIn) , Basso, Giuseppe (VerfasserIn) , Niggli, Felix (VerfasserIn) , Barisone, Elena (VerfasserIn) , Henze, Günter (VerfasserIn) , Ludwig, Wolf-Dieter (VerfasserIn) , Haas, Oskar A. (VerfasserIn) , Cazzaniga, Giovanni (VerfasserIn) , Köhler, Rolf (VerfasserIn) , Silvestri, Daniela (VerfasserIn) , Bradtke, Jutta (VerfasserIn) , Parasole, Rosanna (VerfasserIn) , Beier, Rita (VerfasserIn) , van Dongen, Jacques J. M. (VerfasserIn) , Biondi, Andrea (VerfasserIn) , Schrappe, Martin (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 14 December 2020
In: Blood
Year: 2010, Jahrgang: 115, Heft: 16, Pages: 3206-3214
ISSN:1528-0020
DOI:10.1182/blood-2009-10-248146
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood-2009-10-248146
Volltext
Verfasserangaben:Valentino Conter, Claus R. Bartram, Maria Grazia Valsecchi, André Schrauder, Renate Panzer-Grümayer, Anja Möricke, Maurizio Aricò, Martin Zimmermann, Georg Mann, Giulio De Rossi, Martin Stanulla, Franco Locatelli, Giuseppe Basso, Felix Niggli, Elena Barisone, Günter Henze, Wolf-Dieter Ludwig, Oskar A. Haas, Giovanni Cazzaniga, Rolf Koehler, Daniela Silvestri, Jutta Bradtke, Rosanna Parasole, Rita Beier, Jacques J.M. van Dongen, Andrea Biondi, and Martin Schrappe
Beschreibung
Zusammenfassung:The Associazione Italiana di Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Acute Lymphoblastic Leukemia (AIEOP-BFM ALL 2000) study has for the first time introduced standardized quantitative assessment of minimal residual disease (MRD) based on immunoglobulin and T-cell receptor gene rearrangements as polymerase chain reaction targets (PCR-MRD), at 2 time points (TPs), to stratify patients in a large prospective study. Patients with precursor B (pB) ALL (n = 3184) were considered MRD standard risk (MRD-SR) if MRD was already negative at day 33 (analyzed by 2 markers, with a sensitivity of at least 10(-4)); MRD high risk (MRD-HR) if 10(-3) or more at day 78 and MRD intermediate risk (MRD-IR): others. MRD-SR patients were 42% (1348): 5-year event-free survival (EFS, standard error) is 92.3% (0.9). Fifty-two percent (1647) were MRD-IR: EFS 77.6% (1.3). Six percent of patients (189) were MRD-HR: EFS 50.1% (4.1; P < .001). PCR-MRD discriminated prognosis even on top of white blood cell count, age, early response to prednisone, and genotype. MRD response detected by sensitive quantitative PCR at 2 predefined TPs is highly predictive for relapse in childhood pB-ALL. The study is registered at http://clinicaltrials.gov: NCT00430118 for BFM and NCT00613457 for AIEOP.
Beschreibung:Gesehen am 06.06.2023
Beschreibung:Online Resource
ISSN:1528-0020
DOI:10.1182/blood-2009-10-248146

Ähnliche Einträge